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Abstract: Traumatic spinal cord injury (SCI) is a devastating neurological condition characterized by
a constellation of symptoms including paralysis, paraesthesia, pain, cardiovascular, bladder, bowel and
sexual dysfunction. Current treatment for SCI involves acute resuscitation, aggressive rehabilitation
and symptomatic treatment for complications. Despite the progress in scientific understanding,
regenerative therapies are lacking. In this review, we outline the current state and future potential of
invasive and non-invasive neuromodulation strategies including deep brain stimulation (DBS), spinal cord
stimulation (SCS), motor cortex stimulation (MCS), transcutaneous direct current stimulation (tDCS) and
repetitive transcranial magnetic stimulation (rTMS) in the context of SCI. We consider the ability of these
therapies to address pain, sensorimotor symptoms and autonomic dysregulation associated with SCI.
In addition to the potential to make important contributions to SCI treatment, neuromodulation has
the added ability to contribute to our understanding of spinal cord neurobiology and the pathophysiology
of SCI.
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1. Introduction
Traumatic spinal cord injury (SCI) is a devastating neurological disorder with a reported incidence
in various countries and regions ranging from 10 to 80 million per population per year [1–3]. It is
most commonly caused by road traffic accidents, falls, violence and sports injuries. The incidence and
distribution of causes, and long-term survival rates, vary significantly across the globe, depending upon
a wide range of complex social and economic factors [1,3,4]. It has a 2.5–5 fold higher incidence in
males, with a peak in young adults (age 20–30) [1].
SCI is characterized by a constellation of symptoms including paralysis, paraesthesia, pain,
cardiovascular, bladder, bowel and sexual dysfunction. The level of physical disability depends on
the severity of the injury and the level of injury. The severity of the injury is commonly assessed
by the International Standards for Neurological Classification of Spinal Cord Injury (ISCNSCI)
developed by the American Spinal Injury Association (ASIA). This can be classified into different
grades on the ASIA impairment scale (Table 1). Epidemiological studies suggest that more injuries
occur at the cervical levels than thoracic levels, although the exact distribution varies based on
the geographic location of the studies [1]. SCI has been shown to cause significant autonomic
dysfunction, with neurogenic shock one of the leading causes of death [5].
Arguably at least as important as the physical and physiological disability caused by SCI are
its psychological and economic impacts. SCI predominantly affects a young adult population and
the psychological impact of rendering an independent, healthy individual paraplegic or tetraplegic
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without bladder, bowel or sexual function can be devastating. In addition to the costs associated
with medical care in SCI patients, there is an immense secondary economic burden associated with
individuals incapacitated for most of their prospective career and the subsequent impact upon their
families. One study estimated the lifetime economic burden of 1.5 million 2011 Canadian dollars per
tetraplegic individual [6].
Table 1. The American Spinal Injury Association (ASIA) Impairment Scale.
ASIA Impairment Scale Definition Explanation
A Complete No motor or sensory function is preserved in the sacralsegments S4–S5.
B Incomplete Sensory but not motor function is preserved belowthe neurological level and includes the sacral segments S4–S5.
C Incomplete
Motor function is preserved below the neurological level,
and more than half of the key muscles below the neurological
level have a muscle grade less than 3.
D Incomplete
Motor function is preserved below the neurological level,
and more than half of the key muscles below the neurological
level have a muscle grade of 3 or more.
E Normal Motor and sensory function are normal.
In this review, we briefly outline the current management of acute and chronic SCI and focus on
the potential of neuromodulation strategies in its treatment. In particular, we review the available
clinical evidence for strategies such as deep brain stimulation (DBS), spinal cord stimulation (SCS),
motor cortex stimulation (MCS), transcutaneous direct current stimulation (tDCS) and repetitive
transcranial magnetic stimulation (rTMS) in affecting pain, sensorimotor symptoms and autonomic
dysregulation, all of which are important sequelae in SCI.
2. Current Management of Acute Spinal Cord Injury
The mainstay of current management of acute spinal cord injury involves acute resuscitation
and the prevention of secondary injury to the spinal cord. Acute resuscitation follows Advanced
Trauma Life Support principles with particular importance to the airway and breathing in high
cervical injuries that can impair diaphragmatic function, along with early spinal immobilisation.
Circulatory resuscitation is also of paramount importance due to the phenomenon of neurogenic
shock, which can cause profound bradycardia, hypotension and vasodilatation due to the loss
of sympathetic tone. Standard first procedures include acute stabilisation, clinical assessment
(ASIA score) and computerised tomography and magnetic resonance imaging (CT and MRI).
Secondary injury to the spinal cord may be prevented by maintaining adequate perfusion to
the cord [7,8] and early decompressive surgery [9–11]. There is also a growing body of evidence
supporting intra-spinal cord pressure monitoring and expansion duraplasty for refractory intra-spinal
hypertension, drawing parallels from intracranial pressure monitoring paradigms in traumatic brain
injury [12–15].
There are currently no generally approved medical therapies to improve outcomes in acute
SCI [8], although a number of major trials are ongoing. Riluzole, a blocker of voltage-gated sodium
channels, has shown promise in improving motor function following cervical injury and is currently
the subject of a phase III randomised controlled trial [16–18]. A substance of long-term interest has
been the voltage-gated potassium channel blocker 4-aminopyridine [19], but this has given mostly
disappointing results in acute and chronic human trials examining motor improvement [20–22].
Likewise, steroid treatment (methyl-prednisolone), which some practitioners viewed favourably
in the previous two decades, now appears to offer little benefit and non-negligible risk [8,23].
Induced hypothermia remains a moderately promising therapy for acute SCI [24]. This was
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explored over many decades to treat early traumatic brain injury, although with variable results.
Unfortunately, its critical dependence on both the timing of cooling post-injury and the level of
temperature drop appear to be largely responsible for its variable efficacy in central nervous system
(CNS ) neurotrauma [25,26]. Hypothermia is a typical acute sequela of spinal cord trauma, and is
proposed to be an input to brainstem centers controlling repair, as described below.
Subsequent management involves a combination of intense rehabilitation to optimise functional
outcomes and medical therapies, designed either to prevent complications, such as venous
thromboembolic events, infections associated with indwelling catheters and pressure ulcers and
osteoporosis or to treat specific symptoms such as neuropathic pain.
3. Current Management of Chronic Spinal Cord Injury
Despite the advances of modern molecular and cellular science, there has been little clinical
progress in regenerative and restorative therapies for chronic SCI. In vitro and in vivo models have
often looked promising, but no disease modifying therapies have been successfully translated to
humans [27]. Following SCI, structurally damaged axons are unable to regenerate due to a combination
of a glial inhibitory environment and a fundamental lack of neuronal intrinsic regeneration potential.
These factors contribute to persisting functional neurological impairment. A number of promising
restorative and regenerative therapies, including the delivery of olfactory ensheathing cells to
act as a scaffold [28,29], chondroitinase therapy to limit the glial scar [30] and taxol therapy to
promote microtubule stabilization [31], have sought to target these mechanisms, with limited clinical
success [27].
The various proposals for using CNS stimulation in SCI and other neurotrauma are in part
prompted by the apparent obstacles to other approaches. Electrical stimulation of a discrete anatomical
pathway elicits a natural response that can be helpful, whereas the ultimate benefits of administering
a mixture of slow-acting, powerful drugs with an array of adverse effects and issues of receptor
specificity, timing of actions, dosing regimen, tolerance and spatial targeting remain unclear.
Neurotrophic substances of potential interest additionally run the risk of uncontrolled deleterious
axonal sprouting [32]. The testing of restorative pharmacotherapies to satisfy scientific standards and
regulatory demands can also present major difficulties. Cell transplantation may be free of some of
these problems, but safe functional integration of exogenous cells within solid tissue is also a formidable
task, and there is the potential for tumor formation with some cell types [33,34]. The routine clinical
use of cell transplantation therefore seems to be well beyond the immediate horizon.
4. The Potential Roles for Neurostimulation in SCI
The indications for functional neurosurgery, including deep brain stimulation (DBS), cerebral cortical
stimulation and spinal cord stimulation (SCS), have expanded drastically over the last decade and
now encompass a whole host of neurological disorders including movement disorders, psychological
and psychiatric disorders, pain (including neuropathic pain and primary headache disorders), epilepsy,
disorders of consciousness and cognitive disorders [35,36].
In the context of SCI, functional procedures have the potential to impact upon a number of
different domains, including pain, functional motor/sensory recovery, bladder/bowel function and
cardiovascular autonomic dysregulation. Many of these have been highlighted as important symptoms
to address in large surveys of SCI patients [37,38].
There are three broad strategies for chronic SCI: (i) using technology to restore function
without restoring neural architecture; (ii) taking advantage of plasticity to harness residual circuitry;
and (iii) encouraging active regeneration of injured neurons. These are depicted in Figure 1.
The first strategy involves suppressing or inducing immediate effects. Pain suppression is
an obvious example, and the most clinically developed (see next section). Less obviously, one can
try to evoke or improve some specific movements that have been lost. For example, to facilitate
locomotor movements in incompletely injured individuals, the mesencephalic locomotor region can
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be stimulated, thus overcoming weakness in the spinal central pattern generator [39]. This positive
approach requires in practice some integration with patient input or feedback so that it is turned on
only when safe and needed. A more complex way to provide control signals to stimulators is by
brain-machine interfaces tapping neuronal firing in neocortex that represents motor commands [40].
This has been successfully implemented via wireless control connecting cortical microelectrodes to
lumbar epidural stimulators in monkeys [41]. However, a key obstacle that must be understood and
overcome is the so-called “foreign body response” that reduces the efficacy of implants over time [42].
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Thus DBS in brainstem central grey may also be used to block neuropathic pain. The nearby 
mesencephalic locomotor region (MLR) can be stimulated to activate descending pathways that boost 
the locomotor central pattern generator (CPG) in lower thoracic and upper lumbar segments. Cortical 
stimulation activating corticospinal tracts, whether non-invasively via transcutaneous direct current 
stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS), or invasively with direct 
motor cortex stimulation (MCS), can be used for immediate production of movement or to induce 
adaptive plastic changes in motor output. Cortical commands may also be fed to a brain-machine 
interface (BMI) to control variously situated electrodes for peripheral nerve stimulation (PNS) or 
spinal cord stimulation (SCS). SCS distal to the injury has been used for bladder control; proximal 
SCS can be used block pain; and stimulation at any spinal location can be used to generate 
movements, depending on the degree of completeness of functional loss. The simplicity and 
comprehensiveness of restorative DBS in the brainstem are points in its favour. 
The second strategy focuses on stimulation of pathways assumed to possess considerable 
neuroplasticity in their normal functioning, pre-eminently the cortico-spinal tract [43]. This 
propensity for axonal growth and sprouting can perhaps be exploited by the application of 
stimulation, but it is unclear how exactly to use this to shape a valid, adaptive repair. 
A final strategy that has met with some preclinical success assumes that certain brain regions are 
specifically adapted as centres for repairing recent mild neurotrauma [44–47]. Thus the serotonergic 
raphe nuclei of the brainstem release a cocktail of trophic substances from their ubiquitous axon 
terminals in response to injury-correlated sensory or chemical stimuli (e.g., nociception, 
unconsciousness, hypothermia, circulating cytokines). Stimulation of this feedback loop, or the 
regions that feed into it, such as the midbrain periaqueductal grey (PAG), have been shown to 
enhance early histological and sensory-motor recovery in rats with incomplete thoracic SCI [35–37]. 
A potential advantage of these brain centres is that they are non-eloquent, that is, the applied stimulus 
intensities evoked no observable motor responses or arousal changes, facilitating continuous long-
term stimulation. 
5. Neurostimulation for Pain Following SCI 
Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage” [48]. In the context of SCI, pain is common, affecting over 70% of SCI patients, 
and can be categorised as neuropathic or nociceptive (musculoskeletal) in origin, affecting 34% and 
. Diagram of possible sites f r ti i l
fi
fi . fi i .
i i t t l l t l t i i .
li loco otor region (MLR) can be stimulated to activate descending p thways that
boost the locomotor central pattern generator (CPG) in l wer thoracic and upper lu bar segments.
Cortical stimulation activating corticospinal tracts, whether non-invasively via transcutaneous direct
current stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS), or invasively with
direct motor cortex stimulation (MCS), can be used for immediate production of movement or to induce
adaptive plastic changes in otor output. ortical co ands ay also be fed to a brain- achine
interface (B I) to control variously situated electrodes for peripheral nerve sti ulation (P S) or
spinal cord stimulation (SCS). SCS distal to the injury has been used for bladder control; proximal SCS
can be used block pain; and stimulation at any spinal location can be used to generate movements,
depending on the degree of completeness of functional loss. The simplicity and comprehensiveness of
restorative DBS in the brainstem are points in its favour.
t t f ti l ti f t t i l
l sticity in their normal functio ing, pre-eminently the cortico-spinal tract [43]. This propensity
for axonal gr wth a d sp uting can perhaps be exploited by the application of stimulation, but it is
unclear h w exactly to us this to sh pe a valid, adaptive repair.
fi l t t t t t it li i l t t t i i i
ifi ll t t f i i t il t [ ]. t t i
clei of the brainstem r lease a cocktail of trophic substances from their ubiquitous
axon termi als in re ponse to injury-corr lated sensory or chemical stimuli (e.g., i ti ,
i s ess, hypothermia, circulating cytokines). Stimulation of this feedback loop, or the regions
that feed into it, such as the midbrain periaqueductal grey (PAG), have been shown to nhance early
histologic l and sensory-motor rec very in rats with incomplete thoracic SCI [35–37]. A potential
advantage of these brain c ntres is that they are non-eloquent, that is, the ap lied ti l
i t iti evoked no observable m tor responses or arousal changes, f cilitati g continuous
long-ter stimulation.
Brain Sci. 2017, 7, 18 5 of 17
5. Neurostimulation for Pain Following SCI
Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant
sensory and emotional experience associated with actual or potential tissue damage, or described in
terms of such damage” [48]. In the context of SCI, pain is common, affecting over 70% of SCI patients,
and can be categorised as neuropathic or nociceptive (musculoskeletal) in origin, affecting 34% and 64%
of long-term survivors respectively [49–55]. Pain following SCI is thought to occur due a combination
of abnormal inputs from the injured spinal cord and aberrant reorganisation of cortical circuitry [56,57]
and has been shown to be more common at one year following injury than immediately after [55].
The multifactorial aetiology of SCI-related pain makes it notoriously difficult to treat, especially with
traditional pharmacotherapy [58,59] and the IASP’s Neuropathic Pain Special Interest Group is unable
to currently recommend any interventional strategies for the management of SCI-related pain [60].
The use of neurostimulation to treat pain was reported as early as 1960 [61], predating the Melzack
& Wall gate theory [62]. Current indications of neurostimulation for pain include pain from failed back
surgery syndrome (FBSS), neuropathic pain secondary to peripheral nerve injury (e.g., amputation,
brachial plexus injury), facial pain and headache disorders [63,64]. Interventions can target any part of
an impaired nociceptive pathway, including at the level of the spinal cord, deep brain nuclei or motor
cortex [65,66].
Evidence for the efficacy of DBS in the context of SCI-related pain is limited to a few patients
that form part of small series which have had varying results [63,64,67–73]. The main sites targeted
have been ventralis posterior lateralis (VPL) nucleus of the thalamus and the midbrain central gray,
comprising the periaqueductal grey (PAG) and periventricular grey (PVG). A systematic review
by Previnaire in 2009 recorded 19 cases of the successful implantation of DBS electrodes in SCI
patients following trial stimulation in 36 patients to the VPL ± central gray. Only three (16%) of
these cases reported “long-term success” [69]. DBS of VPL may also have a role in the management
of phantom sensations and pain following SCI [74]. More recently, DBS electrodes in the central
gray in two SCI patients were optimised to provide best analgesia; this study found that very low
frequency stimulation (effectively <0.67 Hz) was most effective in these two patients; added benefits
included a reduction in side effects and a long battery life and the authors emphasized the importance
of allowing time (hours to days) before assessing the efficacy of new stimulation parameters [75].
Improving knowledge of the somatotopic organisation of the PAG may aid optimal electrode targeting,
and given the bilateral pain often experienced by SCI patients, it is likely that most SCI patients
will need bilateral electrodes [76,77]. Based on evidence of the success on cingulotomy for cancer
related pain, Spooner et al. reported a single case of effective analgesia in SCI following DBS to
the rostral anterior cingulate cortex, although this patient was only followed up for four months [78].
A subsequent case series of patients treated with anterior cingulate cortex DBS for chronic pain
of various aetiologies (including 1 with SCI) illustrates its potential for long-term control [79].
Over the years, the lack of randomised controlled clinical trial evidence has led to a decrease in
the number of studies reporting on DBS for pain [57] and this has been confounded by the US
Food and Drug Administration giving DBS for pain “off label” status [80], so that the International
Neuromodulation Society still views intracranial modulation for pain as “investigational” [81].
Another option for SCI-related pain is epidural motor cortex stimulation (MCS), although the limited
reports in the literature suggest that SCI-related pain responds poorly to MCS compared with other pain
syndromes [68,82]. However, the systematic review by Previnaire concluded that MCS may be more
effective than DBS in the context of SCI, providing “long-term success” in four out of seven patients [69].
SCS has been used to treat a variety of pain syndromes for over 40 years and the first reports of its
use for spinal cord injury date back to 1972 [83]. It is based upon the Melzack and Wall gate theory
that stimulation of the large dorsal column fibres will inhibit some of the activity produced by smaller
myelinated and unmyelinated fibres in the dorsal horn [62]. Nashold’s series of 30 patients includes
five with traumatic SCI (three from spinal fractures, one with a gunshot wound and one with a cord
contusion), none of whom had an “excellent” response to the treatment [83]. Since then, reports of
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the utility of SCS for SCI-related pain have been limited and suggest poorer responses in SCI patients
compared to other indications such as failed back surgery and peripheral neuropathy pain [84–86].
This may be explained by injury to the neural circuits underlying its efficacy but we are still far from
understanding the mechanisms underlying the efficacy and failure of SCS, especially in the context of
SCI. Newer modalities of SCS such as burst and high frequency stimulation are yet to be evaluated in
their efficacy for chronic pain after SCI.
Non-invasive neuromodulatory strategies include repetitive transcranial magnetic stimulation
(rTMS) and transcranial direct current stimulation (tDCS), both of which are purported to work on
the basis of altering maladaptive plasticity within pain circuits, affecting nuclei in the thalamus and
subthalamic regions [59,87,88]. A recent systematic review identified six studies assessing 127 patients
with neuropathic pain treated with rTMS following SCI. It concluded that although there was some
reduction in pain indices following rTMS, this did not reach statistical significance [89]. There are
many unresolved controversies within the field of rTMS including the location (motor cortex versus
premotor cortex/dorsolateral prefrontal cortex), type and orientation of coil, schedule of repetitive
stimulation and persistence of therapeutic response [90–93]. However, given the non-invasive nature
of rTMS, it could prove a useful tool both in terms of mechanistic understanding and therapeutic
benefit for pain following SCI. It may have a role in predicting responsiveness to MCS and the ability
to influence phantom sensations after SCI, which could provide significant functional benefits for these
patients [94,95]. tDCS is less well characterised, and differs from rTMS in that it does not result in
neuronal firing but changes the resting membrane potential, thereby altering neuronal excitability.
It has long-term effects that are thought to be caused by altered neurotransmitter systems [96].
The largest clinical study to date utilised the anode over the primary motor cortex and showed
a reduction in pain VAS scores in 16 patients following SCI. The tDCS was found to alter metabolism
in the subgenual anterior cingulate cortex, left dorsolateral prefrontal cortex and insula, suggesting
an effect of tDCS on the emotional and cognitive components of pain [97]. The evidence in support
of tDCS has led to it being included as part of third-line therapies for neuropathic pain for SCI in
the CanPain guidelines; it is the only neuromodulatory strategy to be included in the guidelines [98].
The future of neurostimulation for pain in SCI lies in improving the level of evidence for
each intervention and identifying subsets of patients and types of pain that benefit from specific
interventions. Presently, DBS for various types of pain can yield a range of effects in different
patients from dramatic and highly pleasing success to disheartening failure, and the factors leading to
these variable outcomes are entirely unclear, although there are some weak statistical predictors [77].
This task will no doubt be aided by homogenisation of the measurement of pre-intervention and
post-intervention data sets, such as the International Spinal Cord Injury Pain Basic and Extended Data
Sets [99,100]. In addition to the rigorous assessment of outcomes, surgical complications must also
be taken into consideration; studies have highlighted the burden of complications associated with
implanted stimulators, which can impact upon quality of life and overall outcomes [69].
6. Neurostimulation for Sensorimotor Recovery Following SCI
There is little in the way of clinical evidence for the efficacy of neuromodulation for locomotor
and sensory recovery following spinal cord injury. Perhaps the best evidence for efficacy of DBS in
animal models comes from two landmark studies, showing the efficacy of DBS in improving gait in
cord injured rats. The two studies used different targets, the mesencephalic locomotor region (MLR)
and the nucleus raphe magnus and the PAG [39,47], and deliver improvement in different time frames
(immediate or long-term). The correlates of this circuitry in humans need to be better understood,
especially since the efficacy of stimulation for motor responses depends on the number of residual
fibres within the injured cord [101].
Similar rodent and mammalian evidence also exists for SCS, which has been improved by
the use of closed-loop feedback systems to refine stimulation parameters and improve gait [102–104].
The putative role for SCS can also be extrapolated from studies observing motor benefit in patients
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and animals with Parkinson’s disease [105,106] and multiple sclerosis [107,108] undergoing SCS.
There is preliminary human evidence to suggest that epidural SCS may be efficacious in producing
electrophysiological improvements in patients with SCI [109–111]. Further work is necessary to
translate these electrophysiological improvements into functional benefits. Developing a better
understanding of the pattern generator for human gait may also indicate a use for lumbosacral
epidural stimulation, obviating the need for supraspinal inputs [112]. This concept of using
stimulation to replace lost supraspinal input has recently been demonstrated in a primate model,
which relies on real-time input of cortical signals to optimise lumbar epidural stimulation [41,113].
However, this model is limited by the lack of a sensory feedback system, which would further optimise
motor functional recovery.
Animal evidence also exists for the utility of combined MCS and spinal tDCS in promoting
motor recovery after pyramidotomy, suggesting that stimulation proximal and distal to the injury
could facilitate the improvement in function following SCI [114]. TMS may also have a role in motor
recovery, as it has been shown to elicit EMG responses below the level of injury in individuals with
motor-complete SCI; it may therefore have a role in identifying individuals who may benefit from
neuromodulatory therapies or have a therapeutic role in its own right [115,116].
7. Neurostimulation for Autonomic Recovery Following SCI
Autonomic functions, including bladder, bowel and sexual function, have consistently been
highlighted as priorities for recovery in patients with SCI [37,38]. In the acute phase, bladder dysfunction
often manifests as a “flaccid paralysis” resulting in urinary retention requiring catheterisation.
In the chronic phase, this progresses into detrusor hyperreflexia and detrusor-sphincter dyssynergia
resulting in incontinence and incomplete voiding; the mainstay of current treatment is intravesical
botulinum toxin injection which requires repeated treatments every few months and does not address
the dyssynergia [117,118]. Sexual dysfunction can manifest in a number of different ways in
males and females, depending upon the level and completeness of the injury [117]. In addition to
the physical impact, sexual dysfunction in particular may impact psychological wellbeing and overall
quality of life [119,120]. Gastrointestinal disturbances in SCI are common (>60%) and wide-ranging,
including delayed gastric emptying, abnormal colonic myoenteric activity and sphincter/defecation
dysfunction [117,121,122]. The lower GI disturbances are consistent with a “spastic” paresis of
the bowel. The increased colonic muscle tone, abnormal rectal compliance and tight external sphincters
require laxatives and digital reflex stimulation to promote bowel emptying [117,123].
Cardiovascular autonomic dysfunction is a major problem in SCI, and contributes to the excess
cardiovascular mortality in SCI [124]. In the acute phase, the loss of sympathetic outflow can lead to
devastating hypotension, hypothermia and dysrhythmias [125]. In the chronic phase, especially after
cervical or high thoracic injuries, disturbances such as orthostatic hypotension and autonomic
dysreflexia (sudden drastic episodes of elevated blood pressure and bradycardia) have been shown to
be common in SCI patients, which may contribute to the increased cardiovascular disease risk and also
affect other aspects of recovery such as rehabilitation and cognitive function [5,125–128]. SCI can also
lead to thermoregulatory dysfunction.
Although there is little in the way of evidence for autonomic manipulation in the context of
SCI, evidence from other conditions indicate that neuromodulation strategies may have a role [129].
There is evidence that DBS can affect urinary symptoms and control in Parkinson’s disease, dystonia,
essential tremor and chronic pain [130–133]. These studies show a predominant effect on lower urinary
tract symptoms and mechanistic studies have shown that this might be due to enhanced processing
of bladder information following subthalamic nucleus DBS. In the context of SCI, this could prove
beneficial in patients with incomplete SCI, where enhancement of residual sensory inputs could
improve continence. In one study where patients had PAG stimulators for chronic pain, the maximum
cystometric capacity increased during saline infusion into the bladder when the stimulators were
switched on, indicating a switch to the “filling” state over the “voiding” state [134]. However, a deeper
Brain Sci. 2017, 7, 18 8 of 17
understanding of the subcortical networks involved in urinary continence in health and how they
are disturbed in SCI are required. A single patient has also been reported in the literature to have
improved bowel symptoms following subthalamic nucleus DBS for Parkinson’s, which may provide
benefit via a similar mechanism [135].
DBS has also been shown to affect blood pressure with dorsal central gray stimulation resulting
in an increase in blood pressure and ventral central gray stimulation resulting in a decrease in blood
pressure [136–141]. There are therefore potential avenues to treat both the orthostatic hyptension and
autonomic dysreflexia seen in SCI patients. Ventral versus dorsal DBS in the central gay has also
been shown to alter different frequency components of heart rate variability, suggesting differential
contributions of parasympathetic and sympathetic nervous systems to its mechanisms of action [142].
A number of other neuromodulatory strategies have also been reported for autonomic recovery,
specifically for bladder, bowel and sexual function [118]. Although the sacral anterior root stimulator
(Brindley device) has been shown to be successful at overcoming detrusor-sphincter dyssynergia and
achieving and sustaining continence in 88% of 500 patients at a mean of four years follow-up [143],
the negative impacts of deafferentation of the posterior nerve roots on bladder, bowel and sexual
function has seen its use decline [118]. More recent evidence of using the same device for anterior and
posterior root stimulation has shown promise [144,145]. Sievert and colleagues present compelling
data that early (median 2.9 months following injury) insertion of sacral nerve modulators into the S3
nerve roots can improve urinary continence, bowel function and even help achieve erection in patients
with complete SCI [144].
8. The Future of Neurostimulation in SCI
The plethora of applications for neuromodulation in SCI provides promise in a field currently
devoid of disease-modifying therapies. The physiological, psychological and economic benefits
associated with addressing issues such as pain, mobility and autonomic symptoms in SCI patients
is large. Given the current dearth of treatment options, neuromodulation is an attractive emerging
option. However, there are a number of outstanding questions that first need to be answered.
Apart from the need to identify evidence-based indications for deep brain, motor cortex and spinal
cord stimulation and the non-invasive strategies in the context of SCI, we also need a more nuanced
understanding of the patient, injury and treatment factors that influence success. Specifically, the timing
of interventions seems a crucial variable. The interventions for pain have thus far been performed many
months to years after the injury once aberrant circuitry has become established and it remains to be
explored whether more acute interventions could be more beneficial at preventing the development of
maladapted circuits or promote regeneration [146]. Another key variable are the stimulation parameters.
As recent studies have shown, parameters that are vastly different to what is commonly used may be
more beneficial [75] and optimisation of parameters may be aided by closed-loop feedback systems,
as has been tentatively shown in Parkinson’s disease [147,148].
The potential, in particular, of PAG DBS for addressing multiple symptoms is intriguing.
The animal and human evidence presented earlier in this review have illustrated the potential to
address pain, autonomic features and facilitate motor recovery in SCI. The fact that PAG is already
a target in human DBS for pain makes it an ideal candidate for further investigation to target
the disabling triad of pain, autonomic dysreflexia (both cardiovascular and sphincteric) and paralysis.
Mechanistic insight studies, both in humans and animals, will also aid progress in the field.
In particular, human electrophysiological and imaging studies in spinal cord injury both before and
after neurostimulator implantation will allow us to develop a better understanding the biological
processes underlying symptomatic improvement. For example, despite the use of DBS in the central
gray for pain, the mechanism of action remains unclear [149]. Theories implicating endorphins and
opioid pathways have since been disproven [150–152]. More recent evidence has shown that DBS and
SCS may modulate gene expression [153,154]. An understanding of these modifications may provide
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insight into the failure of CNS regeneration following injury. However, as with other SCI studies,
translation of mechanistic understanding in animals to humans must be approached with caution [27].
Technological advances will also be of direct relevance to this field. Smaller nanodevices for
stimulation may improve the specificity and reduce the side-effect profile. Such devices have also
been reported to promote axonal regeneration in the cord [155] and may allow access to previously
inaccessible nuclei, such as the nucleus raphe magnus that has been shown to improve gait in rats [47].
Crucial to providing conclusive evidence of efficacy is well designed clinical trials with relevant
outcome measures that are able to be consistently replicated. Much is to be learnt from the failure
of medical therapies such as steroids [156]. Trials in SCI will never be able to recruit large numbers,
which places added importance on trial design. An abundance of prognostic factors (ASIA score on
admission, age, level of injury, rehabilitation) increases heterogeneity in SCI trials. Adaptive trial
designs or n-of-1 trials [157] may be important in the context of neuromodulation, as will be improving
our understanding of factors influencing outcome in SCI patients. Using established frameworks
such as the IDEAL recommendations and using homogenised core outcome sets will be important to
systematic evaluation of these new technologies [158,159].
Despite the potential of neuromodulation strategies, the limitations must also be taken into
consideration. All implants and surgical procedures are associated complications such as the foreign
body response that reduces efficacy over time [42]. Specifically, the risks of functional compromise
associated with damage to residual neural structures in SCI patients may be higher than in
other disorders.
9. Conclusions
Despite the current paucity of clinical evidence for efficacy, functional neurosurgery has
the potential to make contributions to the treatment of SCI. It can immediately relieve some of
the many visceral and sensory-motor deficits and has the potential to effectuate some useful degree of
reversal of the underlying neurodegeneration, albeit partially, by exploiting the capacity of electrical
activity to increase sprouting or induce other plastic changes in neural pathways, such as maturation
and integration of endogenous neural progenitor cells.
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